GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosyntech Inc (OTCPK:BSYI) » Definitions » EBIT

Biosyntech (Biosyntech) EBIT : $-10.86 Mil (TTM As of Dec. 2009)


View and export this data going back to 2000. Start your Free Trial

What is Biosyntech EBIT?

Biosyntech's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2009 was $-3.17 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2009 was $-10.86 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biosyntech's annualized ROC % for the quarter that ended in Dec. 2009 was -81.94%. Biosyntech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2009 was -829.84%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.


Biosyntech EBIT Historical Data

The historical data trend for Biosyntech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyntech EBIT Chart

Biosyntech Annual Data
Trend Mar00 Mar01 Mar02 Mar03 Mar04 Mar05 Mar06 Mar07 Mar08 Mar09
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.93 -5.50 -7.14 -9.18 -8.72

Biosyntech Quarterly Data
Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.56 -2.05 -2.33 -3.32 -3.17

Competitive Comparison of Biosyntech's EBIT

For the Biotechnology subindustry, Biosyntech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyntech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biosyntech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biosyntech's EV-to-EBIT falls into.



Biosyntech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2009 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosyntech  (OTCPK:BSYI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biosyntech's annualized ROC % for the quarter that ended in Dec. 2009 is calculated as:

ROC % (Q: Dec. 2009 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2009 ) + Invested Capital (Q: Dec. 2009 ))/ count )
=-12.68 * ( 1 - 0% )/( (14.386 + 16.564)/ 2 )
=-12.68/15.475
=-81.94 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2009) data.

2. Joel Greenblatt's definition of Return on Capital:

Biosyntech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2009 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2009 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2009  Q: Dec. 2009
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-12.68/( ( (1.542 + max(-2.157, 0)) + (1.514 + max(-0.842, 0)) )/ 2 )
=-12.68/( ( 1.542 + 1.514 )/ 2 )
=-12.68/1.528
=-829.84 %

where Working Capital is:

Working Capital(Q: Sep. 2009 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.316 + 0.03 + 0.249) - (2.23 + 0.522 + 0)
=-2.157

Working Capital(Q: Dec. 2009 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.145 + 0.03 + 0.397) - (1.376 + 0.038 + 0)
=-0.842

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2009) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biosyntech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2009 )
=-10.858/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosyntech EBIT Related Terms

Thank you for viewing the detailed overview of Biosyntech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyntech (Biosyntech) Business Description

Traded in Other Exchanges
N/A
Address
475 Boulevard Armand-Frappier, Laval, QC, CAN, H7V 4B3
Biosyntech Inc is engaged in developing advanced biotherapeutics thermogels specifically designed for tissue repair and delivery of therapeutic agents. The company's products include BST-CarGel, BST-InPod, BST-DermOn, BST-Ossifil and BST-Ossifix and BST-Disc for intervertebral disc restoration.

Biosyntech (Biosyntech) Headlines

No Headlines